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ABSTRACT
Drug distribution within its carrier in a solid dosage form often generates a profound
influence on its release profile, particularly when the physicochemical properties of the
carrier are exploited to manipulate drug release behavior. In this job, two different types
of distributions of a model drug ibuprofen (IBU) within a protein gliadin in their
electrospun nanofibers were intentionally created. One was homogeneous distribution in
the monolithic fibers fabricated using a modified coaxial process, and the other one was
heterogeneous distribution in the core/shell fibers prepared through a traditional coaxial
process. SEM observations clearly demonstrated the different distributions of IBU
within gliadin in the two kinds of nanofibers although both of them had smooth surfaces
and linear morphology. XRD results showed that IBU was amorphously distributed in
the monolithic fibers, but that some IBU crystalline lattices presented in the core/shell
fibers. FTIR and RM spectra suggested that gliadin had good compatibility with IBU. In
vitro dissolution tests verified that the gliadin nanofibers with a heterogeneous drug
distribution could provide a better sustained release profile than its counterpart in terms
of initial burst release and sustained release time period. Both the fiber formation and
drug-controlled release mechanisms are suggested. The present study demonstrated a
concept that drug distribution with the medicated nanomaterials can be exploited as a
tool to optimize the drug sustained release profile.
Keywords: Gliadin, coaxial electrospinning, drug-loaded fibers, sustained release, drug
distribution
Chemical compounds studied in this article
Gliadin (PubChem CID: 17787981); Ibuprofen (PubChem CID: 3672);
1,1,1,3,3,3-Hexafluoro-2-propanol (PubChem CID:13529); Ethanol (PubChem CID: 702);
Trifluoroacetic acid (PubChem CID:6422); Trifluoroethanol (PubChem CID:6409).
1. Introduction
Conventional drug delivery systems (DDSs) potentially exhibit an uncontrollable
initial burst of release, which results in the oscillation of the systemic drug
concentration, leading to both under- and overdosing. A much better therapeutic
outcome is usually achieved if the drug can be maintained at a constant concentration
in the body (Kazemimostaghim et al.，2015; Kim et al., 2016); in this case, the
sustained release of the drug from a DDS is often required for optimum therapeutic
effects (Paliwal and Palakurthi, 2014). Sustained (or extended) release DDSs free the
loaded drug over a prolonged duration, providing a close to constant systemic
concentration. By ensuring that this concentration remains within the therapeutic
window, they provide high therapeutic efficacy with minimum side effects (Babić, 
2015). As they reduce the dosage interval required for successful treatment, oral
sustained-release DDSs tend to have good patient compliance (Liu and Feng, 2015).
For this reason, materials and methods providing sustained drug release profiles have
been widely investigated, with a vast array of reports in the literature. A wide range of
formulation types and carriers have been explored, such as Eudragit RLPO®
nanoparticles prepared by nanoprecipitation (Gandhi et al., 2015), drug loaded in
spherical and tubular nanocarriers via layer-by-layer (LbL) encapsulation (Shutava et
al., 2014), TC(tetracycline) loaded onto Ag@SiO2-MIP (molecularly imprinted
polymers) (AguilarAarcía et al., 2016), gelatin–montmorillonite nanoparticles
prepared by desolvation (Sarmah et al., 2015), microparticles prepared by
spray-drying method and polymeric nanofibers fabricated using electrospinning
(Sóti et al., 2015) .
When developing new drug delivery systems, considering both the type of
material and the physical properties of the formulation (e.g. its size, structure and
shape) is important. The reason is that all these factors can have a significant
influence on the release profile of the drug (Peltonen et al., 2010). Selecting a carrier
material that is biocompatible is also vital (Kazemimostaghim et al.，2015). To this
end, natural polymers, such as gliadin, have attracted much research attention.
Proteins are popular in developing new kinds of nano drug delivery systems for
poorly water-soluble drugs (He et al., 2013; Bohr et al., 2014; Babitha et al., 2017).
Gliadin is a plant protein with good biocompatibility and biodegradability (Gulfam et
al., 2012). Being derived from natural sources, it does not suffer from the presence of
monomer or initiator residues, which can bring problems to the synthetic materials
(Elzoghby et al., 2012). The use of plant protein is also more “environmentally
economical” compared with animal-derived proteins (Wan et al., 2015). Gliadin has
been studied extensively: for instance, fibers with excellent mechanical property and
water stability have been prepared using wet spinning (Reddy and Yang, 2008), and
nanoparticles for food-grade colloidal delivery systems have been reported (Joye et al.,
2015). The application of gliadin microspheres as carriers for drug/nutrient delivery
have been explored further (Wan et al., 2015). Although there exist several reports on
the electrospinning of gliadin, in which acid or basic solutions have been explored as
working fluids with the help of additives, such as polyhedral oligomeric
silsesquioxane (Soares et al., 2011; Wang et al., 2012), no report has yet to explore the
applications of electrospun gliadin fibers in drug delivery to the best of our
knowledge. According to the most recent investigations, these medicated gliadin
fibers have the potentials to be developed into commercial tablets or capsules
(Démuth et al., 2016; Illangakoon et al., 2015).
Electrospinning has evoked considerable interest as a simple, versatile, and
economical method to produce polymer fibers and polymer-based nanocomposites
(Rosic et al., 2012; Yu et al., 2017; Yang et al., 2017). The electrospun fibers often
have micro- to nano-meter sizes with a series of unique characteristics, such as a large
surface area to volume ratio and high porosity (Ji et al., 2013). In virtue of these
characteristics, electrospun fibers have been broadly investigated for potential
applications in a wide variety of fields. These include, for instance, removing heavy
metals from wastewater (El-Sherif et al., 2013; Taha et al., 2012; Wen et al., 2016) ,
tissue engineering (Ji et al., 2013; Wang et al., 2013), photocatalytic degradation
(Choi et al., 2015; Pascariu et al., 2016), thermal energy storage (Chen et al., 2013),
supercapacitor electrodes (Tolosa et al., 2016), solar cells (Jin et al., 2014),
lithium-ion batteries (Han et al., 2016; Zhu et al., 2016), drug delivery (Borbás et al.,
2016; Paaver et al., 2015; Seif et al., 2015), and military protective clothing (Gorji et
al., 2012).
In terms of biomedical applications, electrospun fibers allow the production of
sophisticated nanostructures with control of the fiber alignment, porosity, and size
possible. This has led to a range of new polymer-based DDSs (Rasekh et al., 2015;
Yang et al., 2016; Yu et al., 2015). However, obtaining high quality medicated fibers
using a simple single-fluid electrospinning process remains difficult, because a series
of parameters can affect the process. For example, many pharmaceutical polymers
have a very narrow electrospinnable concentration window, which depends on both
the polymer and solvent characteristics (Pelipenko et al., 2015). In the literature, many
medicated fibers have been fabricated from a co-dissolving solution of a guest drug
and a host polymer using a single-fluid or coaxial process (Illangakoon et al., 2015;
Wang et al., 2015; Xu et al., 2015). In these monolithic products, the drug is typically
homogeneously distributed throughout the resultant fibers. Often, the achievement of
a sustained-release profile depends mainly on the physicochemical properties of the
filament-forming polymer matrix with little considerations about the drug distribution
within the nanofibers. However, drug distributions within the DDSs should have a
deep influence on its functional performance regardless of traditional dosage forms
(Muehlenfeld et al., 2013; Punčochová et al., 2016; Schrank et al., 2015; 
Vukosavljevic et al., 2016; Windbergs et al., 2010) or advanced nano DDSs (Hu et al.,
2016; Huang et al., 2016; Kim et al., 2016; Saeidpour et al., 2017).
In this work, single-fluid electrospinning was first conducted to determine the
electrospinnable concentration window of gliadin. Later, both traditional and modified
coaxial electrospinning processes were carried out to tailor the within-fiber drug
distribution intentionally. Ibuprofen (IBU) was exploited as the model drug because it
is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs),
it has a large consumption all over the world, and it is a typical poorly water-soluble
drug utilized as a model in literature (Li et al., 2013; Zhang et al., 2017; Shen et al.,
2017). Thus, it would be a suitable representative for investigating the influence of
drug distribution on its release behavior. The fibers were characterized in terms of
their morphology, nanostructures, physical forms of components, and drug
sustained-release profiles.
2. Materials and methods
2.1 Materials
IBU was obtained from the Hubei Biocause Pharmaceutical Co., Ltd. (Hubei, China).
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, purity 99.0%), wheat gliadin (extracted
from wheat), anhydrous ethanol, trifluoroacetic acid, and trifluoroethanol were
provided by the Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Water was
double distilled before use.
2.2. Electrospinning
Two syringe pumps (KDS100 and KDS200, Cole–Parmer, Vernon Hills. IL,
USA) and a ZGF2000 high-power supply (60 kV/2 mA, Shanghai Sute Corp.,
Shanghai, China) were used for all electrospinning experiments, together with an
in-house coaxial spinneret. Fibers were collected on a flat piece of cardboard covered
with Al foil.
2.2.1. Gliadin electrospinnability
Gliadin solutions with concentrations of 5, 10, 15, 20 and 25% (w/v) were
prepared by adding appropriate amounts of gliadin powder to HFIP and stirring until
homogeneous solutions were produced. The pump used to drive the sheath liquid was
switched off for these experiments, and the liquids were pumped through the core
channel only. Electrospinning was conducted under ambient conditions (22 °C ± 5 °C,
and relative humidity of 58% ± 6%). After some initial optimization, the distance
between the tip of the spinneret and the collector, the applied voltage, and the flow
rate were fixed at 14 cm, 15 kV, and 2.5 mL/h, respectively.
2.2.2. Coaxial electrospinning
For the successful implementation of a coaxial electrospinning processes, only
one of the two working fluids must be electrospinnable (Huang et al., 2006). Although
the spinnable sheath fluid is traditionally required, many reports using a spinnable
core and unspinnable sheath (commonly called “modified coaxial electrospinning”)
can be found in the literature (Wang et al., 2015). Specifically, pure solvents can be
utilized as sheath fluids to help prevent clogging and ensure the production of high
quality fibers (Yu et al., 2012).
In the traditional coaxial processes, an IBU solution in HFIP was used as the core
fluid, with a gliadin sheath solution. In the modified process, HFIP formed the sheath
fluid, and a mixed gliadin/IBU solution comprised the core. After some optimization,
the core-to-sheath fluid flow rate ratios were fixed at 0.5:2.5 mL/h and 2.5:0.5 mL/h
in the traditional and modified coaxial processes, respectively. The applied voltage
was fixed at 15 kV, and the fibers were collected on aluminum foil at a distance of 14
cm from the tip of the spinneret (see Table 1). The compositions of the working fluids
for the coaxial processes are also listed in Table 1.
2.3. Characterization
2.3.1. Morphology
The surface and cross-section morphology of the electrospun products were
assessed using a Quanta 450 FEG field emission scanning electron microscope
(FESEM; FEI Inc., Hillsboro, OR, USA). The samples were gold sputter-coated under
a nitrogen atmosphere before examination. Images were then recorded at an excitation
voltage of 20 kV. The samples of cross-sections were prepared by immersing a strip of
non-woven mats into the liquid nitrogen for over 20 minutes, followed by the manual
breaking of the strip. The fiber diameters were estimated using ImageJ software on
the SEM images and over 100 places.
2.3.2. Physical form
X-ray diffraction (XRD) patterns were obtained using a D8 Advance
diffractometer (Bruker Corporation, Karlsruhe, Germany) over the 2θ range of 5° – 
60° at 8°/min. The instrument was supplied with Cu Kα radiation (λ = 1.5418 Å) at 40 
mV and 40 mA.
2.3.3. IR and Raman spectroscopy
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) analysis was
conducted using a Spectrum 100 FTIR spectrometer (Perkin Elmer, Waltham, MA,
USA). The scanning range was 500 cm-1– 4000 cm-1, with a resolution of 2 cm-1.
Raman spectra were obtained at room temperature, using a LabRAM HR Evolution
spectrometer (Horiba Scientific, Longjumeau, France). Samples were placed on
microscope slides, and Raman spectra were recorded at least three different positions,
over the range of 300 to 3000 cm-1. Excitation was at 532 nm (He/Ne laser, < 10
mW).
2.4. In vitro drug dissolution tests
In vitro release tests were conducted in 50 mL phosphate buffer solution (PBS,
pH=6.8, 0.2 mol/L) with an amount of fibers containing 1.0 mg IBU (i.e. 16 mg of M1
and E1, and 8.5 mg of M2 and E2). All experiments were carried out in a shaking
incubator (BDY-200D, Baidian Scientific Instrument Co. Ltd., Shanghai, China) at a
constant temperature at 37 °C and a rotation rate of 100 rpm. At predetermined time
points, 2.0 mL aliquots were withdrawn and replaced by an equal volume of PBS to
maintain a constant volume. After filtration through a membrane with pore size of 0.45
μm (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China), samples were assayed at 
264 nm using a Lambda 750S UV-vis spectrophotometer (Perkin Elmer, Waltham, MA,
USA). The concentration of IBU was calculated based on a predetermined calibration
curve. All measurements were conducted six times and were reported as mean ± S.D.
3. Results and discussion
3.1. The gliadin electrospinnable window
The most important factors in the preparation of electrospinnable working fluids
are the selection of solvent and the polymer concentration. Often, polymers have a
very narrow electrospinnable concentration window in a particular solvent. Gliadin
could be electrospun into fibers from its acid or basic solutions. However, the use of
acid or basic conditions is undesirable because of the risk of protein degradation. In
this work, we sought to process gliadin without using potentially detrimental additives.
A panel of solvents (including HFIP, anhydrous ethanol, trifluoroacetic acid,
trifluoroethanol and their mixture) was explored for their ability to dissolve gliadin,
and HFIP was determined to be the most suitable one because of its low boiling point
(59 oC) and the fine solubility and stability of gliadin in it. A series of gliadin
solutions with varied concentrations of 5, 10, 15, 20 and 25% w/v were prepared for
electrospinning. The results are given in Fig. 1.
No fibers were generated from the solution containing 5% gliadin, because at
such a low concentration, there were insufficient physical chain entanglements to
form these. Thus, the solution underwent a typical electrospraying process, with
microparticles as the final products (Fig. 1a). These particles had a size of several
microns and a dimpled morphology. The latter arose because, during electrospraying,
the surface of the droplets solidifies to form a rigid membrane, with some
unevaporated solvents remaining. Further evaporation of the solvents causes the
particles to collapse on themselves.
The gliadin solution with a concentration of 25% was too viscous to be drawn by
the electrical forces, and the spinneret was frequently blocked by semi-solid substance
forming around it. Nevertheless, the electrospinning of solutions containing 10, 15
and 20% gliadin could be undertaken relatively continuously and smoothly, and only
an occasional manual removal of semi-solid materials from around the spinneret was
required. The products are shown in Figs. 1b, c and d, respectively. As can be seen, a
concentration of 10% (Fig. 1b) was still too low to support the formation of linear
fibers, and the products had beads-on-a-string or spindles-on-a-string morphologies.
In contrast, the gliadin solutions at 15% (Fig. 1c) and 20% (Fig. 1d) gave fibers with
free of beads and spindles. The former had a smaller and narrower distribution
diameter (0.72 ± 0.21 μm) than the latter (1.76 ± 0.53 μm). Overall, gliadin has an 
electrospinnable concentration window between 15% to 20% w/v when HFIP is used
as the solvent.
3.2. Morphology of the IBU-loaded gliadin fibers
The raw IBU particles have a typical crystalline morphology, comprising short
rods (Fig. 2a), while the raw gliadin powder having a flat globular shape (Fig. 2b).
The SEM images of the drug-loaded fibers’ surfaces consisting of IBU and gliadin are
shown in Fig. 2c to 2f. Fibers M1 and M2 from the modified coaxial processes (Figs.
2c and 2d) had smooth surfaces and linear morphology without any beads-on-a-string
phenomenon. They had narrow diameter distributions of 0.92 ± 0.13 μm and 0.89 ± 
0.14 μm, respectively. In contrast, the core/shell fibers E1 and E2 from the traditional 
coaxial processes had two distinct fiber populations (Figs. 2e and 2f). Many extremely
fine fibers can be observed, along with population sizes of 0.93 ± 0.42 μm and 1.00 ± 
0.37 μm for E1 and E2, respectively. Similar phenomena can be found in the pure 
gliadin fibers that were prepared using single-fluid electrospinning, although these
occurred to a lesser extent. These phenomena suggest that the modified coaxial
processes help create higher quality fibers in terms of fiber size and size distribution.
The fibers M1 and M2 from the modified coaxial processes had a diameter
slightly smaller than E1 and E2, which were formed under the traditional coaxial
processes. This result can be attributed to the use of a pure solvent as the sheath fluid
in the modified process. This sheath solvent can slow down or even prevent the
premature formation of semi-solid substances on the surface of the working fluid jets,
which in turn, helps the jets to be drawn and dried homogeneously for a longer time
period. The presence of a solvent layer surrounding the working polymer solution can
also weaken some negative influences of the surrounding environment and spinneret
on the fluid jets.
The SEM images of the drug-loaded fibers’ cross-sections are shown in Fig. 3.
Just as anticipated, the cross-sections of fibers M1 and M2 (Figs. 3a and 3b and their
upper-right insets, respectively) were smooth without any discernible nanoparticles
resulting from the solid phase separation. In sharp contrast, the cross-sections of fibers
E1 and E2 (Figs. 3c and 3d and their upper-right insets) had a central region. The
central regions had many tiny particles within them, giving a hint about the possible
re-crystallization of IBU nanoparticles from the core pure IBU working solutions
during the traditional coaxial electrospinning processes. This result suggests that the
fibers E1 and E2 from the traditional coaxial processes had the core-shell
nanostructures with the drug being heterogeneously distributed into the gliadin fibers.
3.3. Physical form
XRD analysis (Fig. 4) was undertaken to determine the physical form of IBU in
the drug-loaded fibers. Numerous distinct reflections in the XRD pattern of raw IBU
(Fig. 4a) can be observed, confirming it to be a crystalline material. Meanwhile, pure
gliadin is amorphous, displaying no Bragg reflections and only broad humps in its
pattern (Fig. 4b).
In the XRD patterns of the monolithic fibers M1 and M2 (Figs. 4c and 4d), the
characteristic Bragg reflections of IBU were absent. Thus, the IBU loaded in the fiber
had been fully converted into the amorphous state by the electrospinning process. In
contrast, several characteristic reflections of IBU were detected in the XRD patterns
of E1 and E2 (Figs. 4e and 4f), which were superimposed on an amorphous
background. Hence, as can be clearly seen, at least a portion of the IBU in the fibers
exists in the crystalline state. During the preparation of E1 and E2, the core fluids
were pure IBU solutions of HFIP. After the evaporation of the solvent molecules, the
IBU molecules within the gliadin sheath presumably re-crystallized to minimize the
energy of the system. This could possible for the E fibers because there were no
polymer molecules in the core hindering this process, but not for the M fibers where
the drug and polymer were intimately mixed; thus, the gliadin molecules provided
steric hindrance to recrystallization.
3.4. Component compatibility
Compatibility among their components is important not only for the formation of
composite fibers, but also for their long-term stability. Second-order interactions, such
as hydrogen bonding, hydrophobic interactions, and electrostatic forces between the
drug and polymer should improve compatibility, and can be investigated by FTIR and
Raman spectroscopy. The FTIR spectra of the raw materials and their fibers are given
in Fig. 5a. The chemical structures of IBU and gliadin are shown in Fig. 5b.
In the IR spectrum of pure IBU (Fig. 5a), numerous vibrations are visible: the
absorbance at 2957 cm-1 was assigned to the stretching of the O-H group, that at 1713
cm-1 corresponded to the stretching of the C=O group, whereas the peak at 1230 cm-1
was due to C-O group stretching. Peaks at 1508, 1462, 1420, and 778 cm-1 can be
attributed to the presence of a phenyl group. Gliadin showed a wide absorption band
centered at 3290 cm-1, assigned to the stretching of the H-bonded O-H groups of the
amino acid present in gliadin; two bands of different intensities of 1652 and 1544 cm-1
were associated with the band vibrations of the C=O and C-N groups, respectively.
Comparing the spectra of the fibers M1, M2, E1 and E2 with that of raw IBU,
the IBU phenyl absorption peaks at 1508, 1462, 1420, and 778 cm-1 disappeared, as
did the carboxylate peak at 1713 cm-1 in the majority of cases. Considering the
molecular structures of the two fiber components (Fig. 5b), it can be suggested that
hydrogen bonds may have formed between them. The IBU and gliadin molecules
possess free hydroxyl groups and amino groups, which can act as proton donors, as
well as carbonyl groups that can serve as proton receptors for forming hydrogen
bonds (Fig. 5c). This explains the observations seen for the modified coaxial fibers
M1 and M2.
However, the characteristic peaks of IBU were also not visible in the spectra of
E1 and E2, despite the fact that the XRD indicated the presence of crystalline IBU in
these systems. The failure to achieve signals of IBU re-crystallized nanoparticles
using ATR-FTIR could be attributed to the fact that only a small proportion of the
IBU molecules in the core parts of fibers had re-crystallized, which was too small and
too far away from the fiber surfaces to be detected using the FTIR instrument.
Raman spectra were collected in an attempt to unravel these factors. Results are
shown in Fig. 6. As can be seen, the pure IBU spectrum had peaks at 2719 (O-H
stretching) and 1608, 1463, 1206, 1180, and 1115 cm-1 (corresponding to the phenyl
group), all of which were absent in the spectra of the fibers, thus confirming the
presence of intermolecular interactions (most likely hydrogen bonding) between the
IBU and gliadin. Similar to the IR data, the Raman spectra of E1 and E2 showed no
evidence for the presence of IBU crystals, thus confirming that this phenomenon
occurred because only a small proportion of the total drug loading recrystallized (the
Raman probe had a much greater penetration depth than ATR-FTIR).
3.5. In vitro drug release profiles
The drug release profiles of the fibers are given in Fig. 7a. M1 and M2 showed a
distinct initial burst of release, freeing 39.60% and 38.47% of the incorporated drug
respectively in the first 30 min, respectively. In contrast, E1 and E2 released only
12.59% and 13.20% of their IBU loading in the same period, respectively, thus
demonstrating a much reduced burst effect. After the experiment had been running for
8 h, M1 and M2 released 92.81% and 92.61% of the loaded IBU, respectively, after
which the release profile tailed off. E1 and E2 could sustain drug release much more
effectively, respectively reaching 93.66% and 92.42% release after 16 h before
tailing-off occurred.
To investigate the drug release mechanism, data were analyzed using the Peppas
equation, Q = ktn (Peppas, 1985). In this model, Q is the percentage of drug released, t
is the time, k is the rate constant, and n is the release exponent, indicative of the drug
release mechanism. The regressed equations for M1 and M2 between 0 h and 8 h were
QM1=50.00t0.31 (R2=0.9924) and QM2=50.21t0.30 (R2=0.9918), respectively. Both the n
values were less than 0.45, indicating that IBU release from M1 and M2 was
controlled by a typical Fickian diffusion mechanism. Meanwhile, the results for E1
and E2 were QE1=21.84t0.53 (R2=0.9926) and QE2=23.02t0.51 (R2=0.9904), respectively.
These n values were greater than 0.45, suggesting an apparent diffusion/erosion
mechanism was operational in these systems.
To further compare the release properties of the fibers, the times taken for the
release of 30%, 50%, and 80% of the contained IBU were calculated from their
Peppas model (Fig. 7b). Although the drug contents in the E2 and M2 fibers were
about 1.9-fold higher compared with those in E1 and M1 fibers, the drug release
behaviors from fibers E1 and E2 were similar as well as those from M1 and M2.
These phenomena suggest that the drug contents have almost no influence on the drug
release behaviors. This is because fibers M1 and M2 have the same drug-loaded host
matrix (gliadin), the similar fibers’ diameters and homogeneous drug distribution, and
the same drug diffusion mechanisms. Similarly, E1 and E2 have a similar drug release
behavior. However, fibers M1 and E1 (and also M2 and E2) resulted in significantly
different drug-release behaviors even though they have the same drug contents. Hence,
the different nanostructures and the correspondingly different drug distributions have
played their roles in manipulating the drug release behaviors.
3.6. Fiber formation and drug release mechanisms
Although the fibers from the modified coaxial processes have better quality than
those from the traditional coaxial processes in terms of their fiber sizes and size
distributions, the latter provided better functional performance considering their drug
sustained-release profiles. The drug distributions within the fibers and also their
physical forms contributed to the different release behaviors observed. The modified
coaxial process ensured a smooth and robust preparation process, but resulted in
monolithic fibers with a homogeneous distribution of amorphous IBU in the gliadin
matrix, which in turn resulted in a worse sustained release profile with a more severe
initial burst release effect and a shorter drug release time period.
By taking advantage of the interactions between the electronic energy and
working fluids, electrospinning processes can solidify the fluids within several
decades of milliseconds regardless of how many working fluids simultaneously.
During this extremely fast process, the physical state of components in the working
fluids can be propagated into the solid products without solid phase separations.
Provided the favorable secondary interactions (such as hydrogen bonds, hydrophobic
and electrostatic interactions) exist between the drug and carrier, there should be no
chances for the drug molecules to migrate, to meet and to re-crystallize into
crystalline lattices. Thus here, the modified coaxial process can amorphize IBU from
its co-dissolving solution with gliadin to result in a monolithic composite with a
uniform drug distribution all over the whole fibers.
In contrast, in the traditional coaxial processes the drug was confined inside an
insoluble gliadin sheath layer, which resulted from the use of a drug solution as the
core working fluid. In coaxial electrospinning processes, generally little diffusion
happens between the core and shell fluids owing to the extremely fast drawing and
drying processes (Yang et al., 2016). However, some drug molecules may have
migrated from the core to the sheath fluid during the traditional coaxial processes,
which has been demonstrated in some electrosprayed products (Bohr et al., 2015; Wan
et al., 2014). These migrations should result in the release of some drug molecules at
the very early stages of the experiment.
Fig. 8a schematically depicts the proposed fiber formation mechanisms in the
traditional coaxial processes. In the bending and whipping region, Coulombic
repulsion (fC) from the surface charges on the fluid jets is responsible for the drawing
and thinning of the viscous gliadin solution. The drug molecules may have possibly
moved along the direction of the electric field (fE), which is perpendicular to the
Coulombic drawing. This phenomenon is likely to be aided by the concentration
gradient, given the presence of a concentrated IBU core solution and lack of drug in
the sheath fluid. This would result in some amount of drug being present in the shell
of the fibers. Owing to the favorable interactions between the drug and polymer, any
IBU in the shell would be expected to exist in the amorphous physical form. In
contrast, the IBU in the core can potentially re-crystallize, as demonstrated by the
XRD data in Fig. 4.
A schematic diagram of the proposed drug distribution in the fibers from the two
spinning processes is exhibited in Fig. 8b. M1 and M2 are monolithic fibers with a
homogeneous IBU distribution. The drug release mechanism is a typical Fickian
diffusion mechanism. When they are added to the dissolution medium, water
molecules gradually penetrate into the fibers; then, the IBU molecules dissolve into
this water and permeate out into the bulk dissolution medium. Owing to the
amorphous nature of the IBU, the uniform drug distribution, the large surface area,
and the short diffusion distance for drug molecules close to the exterior of the fibers,
an initial burst release is inevitable.
However, fibers E1 and E2 have a heterogeneous distribution of IBU, where the
drug is concentrated in the core with a minority of molecules proposed to be present
in the shell. The drug release mechanism is thought to rely both on diffusion and
erosion based on the Peppas model, although it should be noted that this model
assumes a uniform distribution of drug throughout the matrix, and thus its results must
be taken with caution here. Given that gliadin is insoluble in water, the IBU can only
be released by diffusion through the fiber shell. The presence of only a small amount
of drug in the shell and the formation of IBU crystals in the core result in a much
slower rate of release for these core/shell systems than for the monolithic fibers. The
differences of drug stability between the monolithic amorphous fibers and the
heterogeneous core/shell fibers with some drug crystalline lattices deserve to be
further investigated.
4. Summary and conclusions
The electrospinnability of gliadin was investigated, and its electrospinnable
concentration window in HFIP was successfully determined to be between 15% and
20% w/v. With gliadin as drug carrier, two kinds of IBU-loaded fibers were fabricated
using two types of coaxial electrospinning processes. SEM observations showed that
all these fibers had linear morphology with smooth surfaces, but the fibers from
traditional coaxial process had a heterogeneous drug distribution in their core/shell
structures, whereas those from the modified coaxial process possessed a
homogeneous drug distribution in their monolithic structures. The different physical
forms of IBU in the different distributions were demonstrated by XRD tests, one was
totally amorphous and homogeneous, and the other was detected to have IBU
crystalline lattices. FTIR and RM spectra suggested that the drug and carrier had good
compatibility. In vitro dissolution tests verified that the gliadin fibers with a
heterogeneous drug distribution had fewer initial burst drug release and a longer time
period release of 16 h, suggesting a better sustained drug release profile than those
fibers having a homogeneous drug distribution who had severe initial burst release
and a shorter release time period of 8 h. The different drug distributions have
manipulated the different release behaviors of the loaded drug molecules, and thus
resulted in different drug sustained release profiles.
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Table and Figure legends
Table 1. Experimental parameters for the fabrication of IBU-loaded fibers.
Fig. 1. SEM images of electrospun gliadin fibers prepared from solutions with
different concentrations in HFIP: (a) 5%, (b) 10%, (c) 15%, and (d) 20%.
Fig. 2. Surface SEM images of raw materials and drug-loaded fibers. (a) IBU, (b)
gliadin; (c) M1, (d) M2, (e) E1, and (f) E2.
Fig. 3. SEM images of the cross-section of drug-loaded fibers. (a) M1, (b) M2, (c) E1
and (d) E2.
Fig. 4. X-ray diffraction patterns of (a) IBU, (b) gliadin (c) M1, (d) M2, (e) E1 and (f)
E2.
Fig. 5. (a) IR spectra of the raw materials and drug-loaded fibers, together with (b) the
molecular structures of IBU and gliadin, and (c) a schematic showing possible
hydrogen bonding interactions.
Fig. 6. Raman spectra of (a) IBU, (b) gliadin, (c) M1, (d) M2, (e) E1, and (f) E2.
Fig. 7. In vitro drug release data. (a) IBU release as a function of time (n=6; data
reported as mean ± S.D.), and (b) the time needed to release various
percentages of the IBU content.
Fig. 8. Schematic diagrams showing (a) the proposed formation mechanism of the
core/shell fibers from the traditional coaxial process, and (b) the drug
distributions within fibers prepared from the different coaxial spinning
modalities.
Table 1. Experimental parameters for the fabrication of IBU-loaded fibers.
a These values are theoretically calculated according to the compositions and flow rates of the
working fluids.
Process
Core fluid
composition
(w/v)
Sheath fluid
composition
(w/v)
Core/sheath
fluid flow rates
(mL/h)
Drug content in
fibers (%) a
M1
Modified
coaxial
1% IBU
15%gliadin HFIP 2.5/0.5 6.25
M2 2% IBU15%gliadin HFIP 2.5/0.5 11.76
E1 Traditional
coaxial
5% IBU 15% gliadin 0.5/2.5 6.25
E2 10% IBU 15% gliadin 0.5/2.5 11.76
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Fig. 7. In vitro drug release data. (a) IBU release as a function of time (n=6; data
reported as mean ± S.D.), and (b) the time needed to release various
percentages of the IBU content.
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